

Literature CYFRA21.1

1. Stieber P, Hasholzner U, Bodenmüller H, Nagel D, Sunder-Plassmann L, Dienemann H, et al: CYFRA 21-1 - A new marker in lung cancer. *Cancer*, 72S: 707-713, 1993.
2. Ebert W, Dienemann H, Fateh-Moghadam A, Scheulen M, Konietzko N, Schleich T, et al: Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron specific enolase in lung cancer. Results of an international multicentre study. *Eur J Clin Chem Clin Biochem*, 32: 189-199, 1994.
3. Molina R, Agusti C, Mane JM, Filella X, Joseph J, Gimenez N, et al: CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. *Int J Biol Markers*, 9: 96-101, 1994.
4. Paone G, De Angelis G, Munno R, Pallotta G, Bigioni D, Saltini C, et al: Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA 21-1. *Eur Respir J* 8: 1136-1140, 1995.
5. Niklinski J, Furman M, Chyczewska E, Chyczewski L, Rogowski F, Laudanski J: Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer. *Eur Resp J* 8: 291-294, 1995.
6. Scheulen ME, Klanig H, Wiefelspütz JK, Kšmper P, Wagner B, Konietzko N, et al: Pre-therapeutic evaluation of cytokeratin fragment 19 (CYFRA 21-1) in 240 patients with lung cancer in comparison to CEA, NSE, SCC-Ag, TPA and TPS. *Tumordiagn Ther* 18: 14-19, 1997.
7. Stieber P, Zimmermann A, Reinmiedl J, Müller C, Hoffmann, H Dienemann H. CYFRA 21-1 in the early diagnosis of recurrent disease in non-small cell lung carcinomas (NSCLC). *Anticancer Res* 19: 2665-2668, 1999.
8. Seregini E, Foa P, Bogni A, Botti C, Cataldo I, Sala M, et al. Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC): Comparison with TPA, CEA, Scc and NSE. *Oncol Reports* 3: 95-101, 1996.
9. *Clin Lab*. 2011;57(11-12):1011-4. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer. Cabrera-Alarcon JL, Carrillo-Vico A, Santotoribio JD, Leon-Justel A, Sanchez-Gil R, Gonzalez-Castro A, Guerrero JM.
10. *Clin Lung Cancer*. 2011 May;12(3):172-9. Epub 2011 Apr 24. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Cedrés S, Nuñez I, Longo M, Martínez P, Checa E, Torrejón D, Felip E.
11. *Lung Cancer*. 2011 Oct;74(1):112-7. Epub 2011 Mar 12. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Hanagiri T, Sugaya M, Takenaka M, Oka S, Baba T, Shigematsu Y, Nagata Y, Shimokawa H, Uramoto H, Takenoyama M, Yasumoto K, Tanaka F.
12. *Br J Cancer*. 2010 Oct 12;103(8):1221-8. Epub 2010 Sep 21. A multi-analyte serum test for the detection of non-small cell lung cancer. Farlow EC, Vercillo MS, Coon JS, Basu S, Kim AW, Faber LP, Warren WH, Bonomi P, Liptay MJ, Borgia JA.